Development of anti cancer drug targeting longevity related gene -SIRT1 using nanotechnology.
Project/Area Number |
23791811
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Obstetrics and gynecology
|
Research Institution | The University of Tokyo |
Principal Investigator |
SONE Kembun 東京大学, 医学部付属病院, 助教 (90598872)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | SIRT1 / DBC-1 / アポトーシス / カスパーゼ / E-cadherin / 子宮内膜 / 子宮体癌 / 細胞接着能 / レズベラトロール / sirtinol / 子宮体癌細胞株 |
Research Abstract |
We elucidated function analysis of SIRT1 and DBC-1 in apoptosis. And We analyzed the function of SIRT1 in endometrium. We confirmed that DBC-1 is targeted for cleavage by caspase-7 during the process of apoptosis. In addition, Endgeneous SIRT1 and DBC-1 localize to the nucleus in healthy cells and to the cytoplasm during apoptosis, and possibly induce apoptosis signal. In endometrium,SIRT1 plays an important role in regulating E-cadherin and induce cell-attachment.and There is possiblility that SIRT1 is related to human cancinogene- sis in endometrium and capacity of an embrio to attach.
|
Report
(3 results)
Research Products
(17 results)
-
[Journal Article] Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.2013
Author(s)
Miyamoto Y, Nakagawa S, Wada-Hiraike O, Seiki T, Tanikawa M, Hiraike H, Sone K, Nagasaka K, Oda K, Kawana K, Nakagawa K, Fujii T, Yano T, Kozuma S, Taketani Y.
-
Journal Title
Oncol Rep.
Volume: 29(1)
Issue: 1
Pages: 51-7
DOI
Related Report
Peer Reviewed
-
[Journal Article] equential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines2012
Author(s)
Miyamoto Y, Nakagawa S, Wada-Hiraike O, Seiki T, Tanikawa M, Hiraike H, Sone K, Nagasaka K, Oda K, Kawana K, Nakagawa K, Fujii T, Yano T, Kozuma S, Taketani Y.
-
Journal Title
Oncology Reports
Volume: 29
Pages: 51-57
Related Report
Peer Reviewed
-
[Journal Article] Regulation of SIRT1 determines initial step of endometrial receptivity by controlling E-cadherin expression2012
Author(s)
Shirane A, Wada-Hiraike O, Tanikawa M, Seiki T, Hiraike H, Miyamoto Y, Sone K, Hirano M, Oishi H, Oda K, Kawana K, Nakagawa S, Osuga Y, Fujii T, Yano T, Kozuma S, Taketani Y
-
Journal Title
Biochem Biophys Res Commun
Volume: 424
Issue: 3
Pages: 604-10
DOI
Related Report
Peer Reviewed
-
[Journal Article] Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.2012
Author(s)
Shoji K, Oda K, Nakagawa S,-Hiraike O, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
-
Journal Title
PLoS One
Volume: 7(5):
Issue: 5
Pages: e37431-e37431
DOI
Related Report
Peer Reviewed
-
[Journal Article] Resveratrol promotes expression on SIRT1 And StAR in rad ovarian granulosa cells2012
Author(s)
Morita Y,Wada-Hiraike O,Yano T,Shirane A,Hirano M,Hiraike H,Koyama S,Oisihi H, Yoshino O,Miyamoto Y,Sone K,Oda K, Nakagawa S,Tsutsui k,Taketani Y
-
Journal Title
an Implicative role of SIRT1 in the ovary Reproductive Biology and endocrinology
Volume: 10
Pages: 14-14
Related Report
Peer Reviewed
-
-
[Journal Article] Multifunctional transpription factor TF II?1 is an activator of BRACA1 function2011
Author(s)
Tanikawa M,Wada-Hiraike O,Nakagawa S, Shirane A,Hiraike H,Koyama S,Miyamoto Y Sone K,Tsuruga T,Nagasaka K,Matsumoto Y, Ikeda Y,Shoji K,Oda K,Fukuhara H,Nakagawa K,Kato S,Yano T,Taketani Y
-
Journal Title
British journal of cancer
Volume: 104
Pages: 1349-1355
Related Report
Peer Reviewed
-
[Journal Article] Multifunctional transcription factor TFII-I is an activator of BRCA1 function2011
Author(s)
Tanikawa M, Wada Hiraike O, Nakagawa S, Shirane A, Hiraike H, Koyama S, Miyamoto Y, Sone K, Tsuruga T, Nagasaka K, Matsumoto Y, Ikeda Y, Shoji K, Oda K, et al
-
Journal Title
Br J Cancer
Volume: 104
Issue: 8
Pages: 1349-1355
DOI
Related Report
Peer Reviewed
-
[Presentation] 子宮体癌リンパ節転移陽性(臨床進行期IIIc)例における予後因子の検討2012
Author(s)
園田正樹、織田克利,有本貴英,武家尾舞子,曾根献文,森繭代,松本陽子,川名敬,中川俊介,矢野哲,上妻志郎,武谷雄二
Organizer
日本婦人科腫瘍学会
Place of Presentation
新高輪プリンスホテル
Year and Date
2012-07-19
Related Report
-
-
-
-
-
[Presentation] 当科での子宮内膜異型増殖症、高分化子宮体癌に対するMPA療法を用いた妊孕性温存治療に関する検討胚細胞性腫瘍に対するBEP療法の有害事象と妊孕性に関する検討2011
Author(s)
宮本雄一郎、佐藤英貴,三浦紫保,長阪一憲,曾根献文,松本陽子,有本貴英,織田克利,川名敬,矢野哲,上妻志郎,武谷雄二
Organizer
日本婦人科腫瘍学会
Place of Presentation
札幌コンベンションセンター
Year and Date
2011-07-22
Related Report
-
-
-